Close
Novotech
Jabsco PureFlo 21 Single Use

News

Lonza Announces New Offering of Silensomes™ HLM for Drug Metabolism Studies

Lonza Walkersville announced its new offering of Silensomes™ Human Liver Microsomes (HLM) products – pooled human liver microsomes for in vitro cytochrome P450 (CYP) phenotyping. CYP phenotyping is a regulatory requirement for new drug candidates to...

Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer’s Diesase

Eisai Co., Ltd. announced that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking...

SOTIO Completes Enrolment of Phase III VIABLE Study in Late Stage Prostate Cancer

SOTIO, a biotechnology company owned by the PPF Group, announced the enrolment of the last patient into the VIABLE study, a global Phase III clinical trial evaluating DCVAC/PCa in combination with docetaxel in patients with metastatic castration resistant prostate...

Singapore eDevelopment’s Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance

Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced that its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife") has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric. In August 2017 SeD announced...

Humane Society International Welcomes First Asian Company to Commit to 100% Cage-free Egg Supply Chain

Humane Society International, one of the world's largest animal protection organizations, is pleased to welcome The Lo & Behold Group, a Singaporean hospitality company, is joining the movement to improve animal welfare in its supply chain by committing to...

GeNeuro and Servier Announce post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017

GeNeuro and Servier announced post hoc analyses of 6-month data from the CHANGE-MS Phase 2b study of GNbAC1 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results showed an anti-inflammatory effect in active...

CRF Health’s TrialMax Touch® Solution Selected for Landmark Global Oncology Study

CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry announced that its TrialMax Touch® solution has been selected by a top ten pharmaceutical company for a landmark global oncology trial....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »